Form 4: Teva Pharmaceuticals Director Roberto Mignone Trades Shares

Director Roberto Mignone reported a transaction involving Teva Pharmaceutical Industries Ltd. ordinary shares, acquiring restricted share units and disposing of some shares.

Summary

• Director Roberto Mignone reported a transaction on June 5, 2026, involving Teva Pharmaceutical Industries Ltd. (TEVA) ordinary shares.
• Mignone acquired 14,492 restricted share units (RSUs).
• These RSUs vested on June 5, 2026, and represent a contingent right to receive one ordinary share or its cash equivalent.
• Additionally, Mignone disposed of 119,807 ordinary shares.
• Mignone also indirectly beneficially owns 367,600 ordinary shares held by Swiftcurrent Master Fund Ltd., where Bridger Management, LLC is the investment adviser and Mignone is the manager.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction report with both acquisitions (RSUs) and disposals of shares, without clear indication of positive or negative market sentiment.

Positives

• Acquisition of 14,492 restricted share units by a director, indicating potential future share ownership.
• Vesting of RSUs on June 5, 2026, suggests fulfillment of performance or time-based conditions.

Negatives

• Disposal of 119,807 ordinary shares by a director.

Risks

• The filing does not explicitly mention any risks.
• Indirect beneficial ownership of a significant number of shares (367,600) through an investment fund managed by the director could introduce complexities or potential conflicts of interest, though Mignone disclaims beneficial ownership beyond his pecuniary interest.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical industry, providing transparency on the trading activities of company directors and officers.

Related Party Transactions

• Roberto Mignone, as manager of Bridger Management, LLC (investment adviser to Swiftcurrent Master Fund Ltd.), has an indirect pecuniary interest in the 367,600 ordinary shares held by the Fund. He disclaims beneficial ownership beyond this interest.

Stakeholder Impact

• Shareholders: The disposal of shares by a director may be interpreted in various ways, but the acquisition of RSUs suggests continued alignment with the company's performance.
• Management: The transaction reflects standard compensation and equity incentive practices for directors.
• Regulatory Bodies: Compliance with Section 16 of the Securities Exchange Act of 1934 is maintained.

Next Steps

• Continued monitoring of Roberto Mignone's beneficial ownership and future transactions.
• Further analysis of Teva Pharmaceutical Industries Ltd.'s overall financial health and strategic direction.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, Insider Trading, Shareholder, Director, Restricted Share Units, Securities Transaction, Beneficial Ownership